Breaking News
Sort by:
Top Post
Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.
Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and […]
CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy
CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with […]
GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study
GenScript USA Inc., the world’s leading life-science research tools and services provider, is collaborating with researchers at […]
Gilead Sciences Completes Acquisition of MiroBio
GMiroBioilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to […]
Calliditas’ Partner STADA Launches the First Medicine Authorized in the EU for Treating Primary IgA Nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its European commercial […]
Breakthrough RNA-based Anti-CancerImmunotherapy Treatments Being Developed by Global Consortium Led by the Hadassah Cancer Research Institute
The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, announced today […]
Tridek-one Closes a €16 Million Financing Round to Develop First-in-class Immune Checkpoint Agonists
Tridek-One SAS (the ‘Company’), a leading biotech start-up specialized in the research and development of […]
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug
Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined […]
GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, […]
The Scottish Medicines Consortium (SMC) Recommends Use of Hansa Biopharma’s Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more